Dihexa // Extreme Synaptogenesis
Reportedly 10 million times more potent than BDNF at forming new synaptic connections. Dihexa crosses the blood-brain barrier orally, activates the HGF/c-Met receptor system, and drives dendritic spine formation at concentrations that make traditional nootropics look like placebo. The most powerful synaptogenic compound ever studied — and the one with the most limited human safety data.
Building new brain connections at 10 million times normal potency.
Dihexa activates the hepatocyte growth factor (HGF) / c-Met receptor system in the brain — the same pathway responsible for tissue regeneration in the liver and other organs. Applied to neurons, this drives formation of new dendritic spines and synaptic connections at extraordinary potency.
Oral — the lowest effective dose.
Given the extreme potency and limited human data, conservative dosing is essential. Start at the lowest reported effective dose and do not escalate without clear reason. Shorter cycles with breaks are the prudent approach.
Wright and Bhatt — the angiotensin IV connection.
Dihexa was developed by Joseph Bhatt and John Wright at Washington State University, published in the Journal of Pharmacology and Experimental Therapeutics (2013). It emerged from research on angiotensin IV and its cognitive effects in aged rats.
The key finding was that Dihexa promoted new synaptic connections at concentrations 10 million times lower than BDNF in cell culture assays. In aged rats with cognitive impairment, Dihexa restored performance in spatial learning tasks (Morris water maze) to levels comparable to young animals.
The mechanism was identified as HGF/c-Met activation — a growth factor system primarily known for liver regeneration. In the brain, HGF/c-Met drives neurite outgrowth and dendritic spine formation. No human clinical trials have been conducted. The cancer concern stems from HGF/c-Met's known role in tumor progression.
Extreme nootropic comparison.
| Compound | Mechanism | Potency | Route | Human Data |
|---|---|---|---|---|
| Dihexa | HGF/c-Met Synaptogenesis | 10⁷x vs BDNF | Oral | None (preclinical) |
| P21 | CNTF Neurogenesis | Moderate | SubQ/Nasal | None (preclinical) |
| Semax | BDNF + NGF | Validated | Intranasal | 30yr clinical (Russia) |
| NSI-189 | Hippocampal Growth | Moderate | Oral | Phase 2 |
What to watch for.
Dihexa's side effect profile is manageable with proper protocol adherence. Baseline blood work before starting and periodic monitoring during use is essential.
- NO human safety data — unknown risk profile
- Theoretical cancer risk (HGF/c-Met drives tumor growth)
- Headache reported anecdotally
- Overstimulation / insomnia at higher doses (anecdotal)
- Blood pressure effects possible (angiotensin IV analog)
- This is the highest-risk compound in the cognitive category
- Comprehensive cancer screening before starting
- PSA (prostate — c-Met related)
- CEA, AFP, CA-19-9 (tumor markers)
- Liver enzymes (ALT, AST — HGF liver pathway)
- Blood pressure monitoring
- Comprehensive metabolic panel
- Complete blood count
- Semax provides safer BDNF foundation — consider before escalating to Dihexa
- P21 for complementary neurogenesis (different mechanism)
- Do NOT combine with other HGF/c-Met activating compounds
- Cancer screening is mandatory before use
- Short cycles (2–4 weeks) with long breaks
- Medical supervision is essential — this is not a casual nootropic
- Store at room temperature or refrigerated
- Protect from moisture and light
- Oral formulation — capsules or measured solution
- Stable at room temperature for oral form
- Research grade — verify source purity
Compounds that complement Dihexa.
The nuclear option for cognitive enhancement — proceed at your own risk.
Dihexa's potency numbers are staggering — 10 million times more potent than BDNF at promoting synaptogenesis. But potency and safety are different conversations. There are zero human clinical trials, the HGF/c-Met pathway is known to drive tumor progression, and the long-term effects of artificially accelerated synaptogenesis are completely unknown. Most users should exhaust Semax, Selank, and other validated compounds before considering Dihexa. If you proceed: comprehensive cancer screening first, shortest possible cycles, lowest effective dose, medical supervision, and the understanding that you are in genuinely uncharted territory. This is the cutting edge — and the cutting edge cuts both ways.
Our free Protocol Guide includes the cognitive peptide hierarchy — validated compounds first, advanced protocols for experienced users, and safety monitoring.